Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shawn Cross was appointed as Director at Cyclo Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On December 27, 2023, effective as of the Effective Time, Shawn Cross, a former director and former Chief Executive Officer of AMTI, was appointed to the Board to serve as a member of the Board, until his successor has been duly elected and qualified, or until his earlier resignation or removal.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Cyclo Therapeutics, Inc. underwent a change of control involving Applied Molecular Transport Inc. for 0.1331 shares of Cyclo Common Stock per share of AMTI Common Stock (closed 2023-12-27).
- Action
- change of control
- Counterparty
- Applied Molecular Transport Inc.
- Consideration
- 0.1331 shares of Cyclo Common Stock per share of AMTI Common Stock
- Closing
- 2023-12-27
Exact text from the filing
Stock held directly by Cyclo or Merger Sub) was automatically converted into the right to receive a number of shares of common stock of Cyclo (“Cyclo Common Stock”) equal to 0.1331 (the “Exchange Ratio”). No fractional shares of Cyclo Common Stock were issued in connection with the Merger and the number of shares of Cyclo Common Stock issued to the AMTI
View on SEC.gov